9-27-09

FFW

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS PAPER AND THE DOCUMENTS REFERRED AS BEING ATTACHED OR ENCLOSED HEREWITH ARE BEING DEPOSITED WITH THE UNITED STATES POSTAL OFFICE ON SEP. 2 4 2004 AS EXPRESS MAIL ADDRESSED TO: MAIL STOP AMENDMENT COMMISSIONER FOR

PATENTS, PO BOX 1450, ALEXANDRIA, VA 22313-1450

Efaine C. Stracker

SEP 2 4 2004

PATENT

Attorney's Docket No.: 00038.04CON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Hale et al.

Serial No .:

10/792,096

Filed:

3/3/2004

Title

DELIVERY OF RIZATRIPTAN OR ZOLMITRIPTAN THROUGH AN

INHALATION ROUTE

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

In accordance with their continuing duty of disclosure under 37 CFR §§ §1.97, 1.98 and 1.56, Applicants hereby submit for consideration in the above-identified application the enclosed references. The Information Disclosure statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

For the convenience of the Examiner, the references are listed on a PTO Form 1449 (attached) and copies thereof are enclosed. Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines than an extension and/or other relief is required, Applicants petition for any required relief including any extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 502731**. Please direct all correspondence to the following customer number.

Respectfully submitted,

Date: 8EP. 2 4 2004

Elaine C. Stracker J.D., Ph.D., Reg. 43,166

Alexza Molecular Delivery Corporation 1001 East Meadow Circle Palo Alto, CA 94303

TEL: (650) 687-3905 FAX: (650) 687-3999

Approved for use through 07/31/2006. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. 10/792,096 Application Number TRANSMITTAL 3/3/2004 Filing Date **FORM** Ron L. Hale First Named Inventor (to be used for all correspondence after initial filing) Art Unit Not yet known **Examiner Name** To be assigned Total Number of Pages in This Submission Attorney Docket Number 00038.04CON **ENCLOSURES** (check all that apply) After Allowance communication Drawing(s) Fee Transmittal Form to Group Appeal Communication to Board Fee Attached Licensing-related Papers of Appeals and Interferences Appeal Communication to Group Petition Amendment / Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert a After Final **Proprietary Information** Provisional Application Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Other Enclosure(s) (please Extension of Time Request Terminal Disclaimer identify below): Request for Refund Express Abandonment Request Information Disclosure Statement CD, Number of CD(s) ___ Certified Copy of Priority Document(s): Remarks Info. Discl. Statemetn (2 pp.)
Form 1449 (3 copies, 7 pages each)
Copy of References /64 Response to Missing Parts/ Incomplete Application Response to Missing Parts Return Postcard under 37 CFR 1.52 or 1.53

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm or ALEXZA MDC, 1001 East Meadow Circle, Palo Alto, CA 94303 Customer Number 37485 Individual name Signature Date SEP. 2 4 2004

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the

Typed or printed name	Elaine C. Stracker		
Signature	Elli Chick	Date	SEP. 24 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

SEP 2 1 2004 By Form PTO 4449

INFORMATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00038.04 CON Application Number: 10/792,096

Applicant: Hale et al.

Filing Date: 3/3/2004 Group Art Unit: Not yet known

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	02/02/1971	3,560,607	Hartley et al.			
•	2.	05/27/1980	Re. 30,285	Babington			
	3.	01/23/1990	4,895,719	Radhakrishnun et al.			**
•	4.	09/17/1991	5,049,389	Radhakrishnun			
	5.	02/14/1995	5,388,574	Ingebrethsen			
	6.	08/13/1996	5,544,646	Lloyd et al.			
	7.	12/09/1997	5,694,919	Rubsamen et al.			
	8.	04/07/1998	5,735,263	Rubsamen et al.			
	9.	04/14/1998	5,738,865	Baichwal et al.			
	10.	06/02/1998	5,758,637	Ivri et al.			
	11.	06/29/1999	5,915,378	Lloyd et al.			
	12.	08/10/1999	5,934,272	Lloyd et al.			
	13.	09/28/1999	5,957,124	Lloyd et al.			
	14.	10/05/1999	5,960,792	Lloyd et al.			
	15.	11/30/1999	5,993,805	Sutton et al.			
	16.	03/28/2000	6,041,777	Faithfull et al.			· · · · · · · · · · · · · · · · · · ·
	17.	04/18/2000	6,051,566	Bianco			
	18.	08/01/2000	6,095,153	Kessler et al.			
	19.	08/15/2000	6,102,036	Slutsky et al.			
	20.	06/05/2001	6,241,969	Saidi et al.			
	21.	07/03/2001	6,255,334	Sands			
	22.	01/14/2003	6,506,762	Horvath et al.			
	23.	02/04/2003	6,514,482	Bartus et al.			
	24.	07/15/2003	6,591,839	Meyer et al.			- , , , , , , , , , , , , , , , , , , ,
	25.	09/06/2001	US 2001/0020147	Staniforth et al.			•
	26.	03/28/2002	US 2002/0037828	Wilson et al.			

EXAMINER:

DATE CONSIDERED:

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00038.04 CON	Application Number: 10/792,096
Applicant: Hale et al.	
Filing Date: 3/3/2004	Group Art Unit: Not yet known

	27.	05/16/2002	US 2002/0058009	Bartus et al.	
	28.	07/04/2002	US 2002/0086852	Cantor	
	29.	08/22/2002	US 2002/0112723	Schuster et al.	
	30.	11/28/2002	US 2002/0176841 .	Barker et al.	
	31.	01/02/2003	US 2003/0004142	Prior et al.	
•	32.	02/13/2003	US 2003/0032638	Kim et al.	

RELATED ALEXZA MOLECULAR DELIVERY CORPORATION PATENT DOCUMENTS

	33.	08/04/2003	10/633,876	Hale et al.
	34.	08/04/2003	10/633,877	Hale et al.
	35.	12/30/2003	10/749,537	Rabinowitz et al.
	36.	12/30/2003	10/749,539	Rabinowitz et al.
·	37.	01/27/2004	10/766,149	Rabinowitz et al.
	38.	01/27/2004	10/766,279	Rabinowitz et al.
·	39.	01/27/2004	10/766,566	Rabinowitz et al.
	40.	01/27/2004	10/766,574	Rabinowitz et al.
	41.	01/27/2004 .	10/766,634	Rabinowitz et al.
	42.	01/27/2004	10/766,647	Rabinowitz et al.
	43.	01/28/2004	10/767,115	Rabinowitz et al.
	44.	01/29/2004	10/768,205	Rabinowitz et al.
	45.	01/29/2004	10/768,220	Rabinowitz et al.
	46.	01/29/2004	10/768,281	Rabinowitz et al.
	47.	01/29/2004	10/768,293	Rabinowitz et al.
·	48.	01/30/2004	10/769,046	Rabinowitz et al.
	49.	01/30/2004	10/769,051	Rabinowitz et al.
	50.	01/29/2004	10/769,157	Rabinowitz et al.
	51.	01/29/2004	10/769,197	Rabinowitz et al.
	52.	02/09/2004	10/775,583	Rabinowitz et al.
	53.	02/09/2004	10/775,586	Rabinowitz et al.
	54.	03/03/2004	10/791,915	Hale et al.

EXAMINER:	DATE CONSIDERED:

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00038.04 CON Application Number: 10/792,096

Applicant: Hale et al.

Filing Date: 3/3/2004 Group Art Unit: Not yet known

	T 66	02/02/0004	10/700 001			
	55.	03/03/2004	10/792,001	Rabinowitz et al.		
	56.	03/03/2004	10/792,012	Hale et al.	ļ	
	57.	03/03/2004	10/792,013	Rabinowitz et al.		
	58.	03/03/2004	10/792,239	Hale et al.		
	59.	03/31/2004	10/813,721	Rabinowitz et al.		
	60.	03/31/2004	10/813,722	Rabinowitz et al.		
	61.	03/31/2004	10/814,690	Rabinowitz et al.		
-	62.	03/31/2004	10/814,998	Rabinowitz et al.		
	63.	04/01/2004	10/815,527	Rabinowitz et al.		
	64.	04/01/2004	10/816,407	Rabinowitz et al.		
	65.	04/01/2004	10/816,492	Rabinowitz et al.		
	66.	04/01/2004	10/816,567	Rabinowitz et al.		
	67.	08/04/2004	10/912,462	Hale et al.		
·	68.	01/23/2003	US 2003/0015196	Hodges et al.		
	69.	04/03/2003	US 2003/0062042	Wensley et al.		
	70.	11/13/2003	US 2003/0209240	Hale et al.		
	71.	01/02/2003	US 2003/0000518	Rabinowitz et al.		
	72.	01/09/2003	US 2003/0005924	Rabinowitz et al.		
	73.	01/09/2003	US 2003/0005925	Hale et al.		
	74.	01/09/2003	US 2003/0007933	Rabinowitz et al.		
	75.	01/09/2003	US 2003/0007934	Rabinowitz et al.		
	76.	01/16/2003	US 2003/0012737	Rabinowitz et al.	- -	
	77.	01/16/2003	US 2003/0012738	Rabinowitz et al.		
	78.	1/16/2003	US 2003/0012740	Rabinowitz et al.	·	
	79.	01/23/2003	US 2003/0015189	Rabinowitz et al.		
	80.	01/23/2003	US 2003/0015190	Rabinowitz et al.		
	81.	01/23/2003	US 2003/0017114	Rabinowitz et al.	1	
	82.	01/23/2003	US 2003/0017115	Rabinowitz et al.		
	83.	01/23/2003	US 2003/0017116	Rabinowitz et al.		
	.84.	01/23/2003	US 2003/0017117	Rabinowitz et al.		
	85.	01/23/2003	US 2003/0017118	Rabinowitz et al.		

EXAMINER:

DATE CONSIDERED:

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00038.04 CON	Application Number: 10/792,096
Applicant: Hale et al.	

Filing Date: 3/3/2004 Group Art Unit: Not yet known

				·
	86.	01/23/2003	US 2003/0017119	Rabinowitz et al.
	87.	01/23/2003	US 2003/0017120	Rabinowitz et al.
	88.	1/30/2003	US 2003/0021753	Rabinowitz et al.
	89.	01/30/2003	US 2003/0021754	Rabinowitz et al.
	90.	01/30/2003	US 2003/0021755	Hale et al.
•	91.	02/20/2003	US 2003/0035776	Hodges et al.
	92.	05/15/2003	US 2003/0091511	Rabinowitz et al.
•	93.	05/27/2004	US 2004/010148	Hale et al.
	94.	07/31/2003	US 2003/0138382	Rabinowitz
	95.	11/06/2003	US 2003/0206869	Rabinowitz et al.
	96.	01/15/2004	US 2004/0009128	Rabinowitz et al.
	97.	05/20/2004	US 2004/0096402	Hodges et al.
	98.	05/27/2004	US 2004/0099269	Hale et al.
	99.	06/03/2004	US 2004/0105818	Hale et al.
•	100.	06/03/2004	US 2004/0105819	Hale et al.
	101.	07/01/2004	US 2004/0126326	Rabinowitz et al.
,	102.	07/01/2004	US 2004/0126327	Rabinowitz et al.
	103.	07/01/2004	US 2004/0126328	Rabinowitz et al.
	104.	07/01/2004	US 2004/0126329	Rabinowitz et al.
	105.	07/01/2004	US 2004/0127481	Rabinowitz et al.
	106.	07/01/2004	US 2004/0127490	Rabinowitz et al.
	107.	08/12/2004	US 2004/0156788	Rabinowitz et al.
	108.	08/12/2004	US 2004/0156789	Rabinowitz et al.
	109.	8/12/2004	US 2004/0156790	Rabinowitz et al.
	110.	08/12/2004	US 2004/0156791	Rabinowitz et al.

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
EXAMINER:			DATE CONSIDERED:				
			ered, whether or not the citation			through the cit	tation if not in

Sheet 5 of 7

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00038.04 CON Application Number: 10/792,096

Applicant: Hale et al.

Filing Date: 3/3/2004 Group Art Unit: Not yet known

		r	1	
	111.	03/14/1990	EP 0 358 114	Europe
	112.	07/03/2001	EP 1 080 720	Europe
	113.	08/29/2001	EP 0 606 486	Europe
	114.	04/11/1996	WO 96/09846	WIPO.
	115.	05/09/1996	WO 96/13161	WIPO
•	116.	05/09/1996	WO 96/13290	WIPO
	117.	05/09/1996	WO 96/13291	WIPO
•	118.	05/09/1996	WO 96/13292	WIPO
	119.	10/03/1996	WO 96/30068	WIPO
	120.	08/07/1997	WO 97/27804	WIPO
	121.	01/22/1998	WO 98/02186	WIPO
	122.	05/28/1998	WO 98/22170	WIPO
-	123.	07/23/1998	WO 98/31346	WIPO
	124.	08/13/1998	WO 98/34595	WIPO
	125.	08/27/1998	WO 98/36651	WIPO
	126.	04/08/1999	WO 99/16419	WIPO
	127.	12/16/1999	WO 99/64094	WIPO
<u></u>	128.	01/06/2000	WO 00/00176	WIPO
	129.	01/06/2000	WO 00/00215	WIPO
	130.	05/18/2000	WO 00/27363	WIPO
	131.	05/25/2000	WO 00/29053	WIPO
	132.	09/17/2000	WO 00/47203	WIPO
	133.	11/02/2000	WO 00/64940	WIPO
	134.	11/09/2000	WO 00/66084	WIPO
	135.	11/09/2000	WO 00/66206	WIPO
	136.	12/21/2000	WO 00/76673	WIPO .
	137.	03/01/2001	WO 01/13957	WIPO
	138.	03/15/2001	WO 01/17568	WIPO
	139.	03/28/2002	WO 02/24158	WIPO

		 	
EXAMINER:	•	DATE CONSIDERED:	

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

	Sheet 0 01 /	
Docket Number: 00038.04 CON	Application Number: 10/792,096	
Applicant: Hale et al.		
Filing Date: 3/3/2004	Group Art Unit: Not yet known	

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	140.	Bennett, R. L. et al. (1981). "Patient-Controlled Analgesia: A New Concept of Postoperative Pain Relief," Annual Surg. 195(6):700-705.
	141.	Carroll, M.E. et al. (1990), "Cocaine-Base Smoking in Rhesus Monkey: Reinforcing and Physiological Effects," Psychopharmacology (Berl) 102:443-450.
	142.	Clark, A. and Byron, P. (1986). "Dependence of Pulmonary Absorption Kinetics on Aerosol Particle Size," Z. Erkrank. 166:13-24.
• .	143.	Darquenne, C. et al. (1997). "Aerosol Dispersion in Human Lung: Comparison Between Numerical Simulations and Experiments for Bolus Tests," <i>American Physiological Society</i> . 966-974.
-	144.	Davies, C. N. et al. (May 1972). "Breathing of Half-Micron Aerosols," Journal of Applied Physiology. 32(5):591-600.
	145.	Dershwitz, M., M.D., et al. (September 2000). "Pharmacokinetics and Pharmacodynamics of Inhaled versus Intravenous Morphine in Healthy Volunteers," <i>Anesthesiology</i> . 93(3): 619-628.
	146.	Finlay, W. H. (2001). "The Mechanics of Inhaled Pharmaceutical Aerosols", Academic Press: San Diego Formula 2.39. pp.3-14 (Table of Contents). pp. v-viii.
	147.	Gonda, I. (1991). "Particle Deposition in the Human Respiratory Tract," Chapter 176, The Lung: Scientific Foundations. Crystal R.G. and West, J.B. (eds.), Raven Publishers, New York. pp. 2289-2294.
-)(-	148.	Hatsukami D., et al. (May 1990) "A Method for Delivery of Precise Doses of Smoked Cocaine-Base to Human." <i>Pharmacology Biochemistry & Behavior</i> . 36(1):1-7.
	149.	Heyder, J. et al. (1986). "Deposition of Particles in the Human Respiratory Tract in the Size Range 0.005-15 μm," J. Aerosol Sci. 17(5):811-822.
	150.	Huizer, H. (1987). "Analytical Studies on Illicit Heron. V. Efficacy of Volitization During Heroin Smoking." <i>Pharmaceutisch Weekblad Scientific Edition</i> . 9(4):203-211.
	151.	Hurt, R. D., MD and Robertson, C. R., PhD, (October 1998). "Prying Open the Door to the Tobacco Industry's Secrets About Nicotine: The Minnesota Tobacco Trial," <i>JAMA</i> 280(13):1173-1181.
	152.	Lichtman, A. H. et al. (1996). "Inhalation Exposure to Volatilized Opioids Produces Antinociception in Mice," <i>Journal of Pharmacology and Experimental Therapeutics</i> . 279(1):69-76 XP-001118649.
	153.	Martin, B. R. and Lue, L. P. (May/June 1989). "Pyrolysis and Volatilization of Cocaine," Journal of Analytical Toxicology 13:158-162.
	154.	Mattox, A.J. and Carroll, M.E. (1996). "Smoked Heroin Self-Administration in Rhesus Monkeys," <i>Psychopharmacology</i> 125:195-201.

EXAMINER:

DATE CONSIDERED:

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00038.04 CON	Application Number: 10/792,096
Applicant: Hale et al.	
Filing Date: 3/3/2004	Group Art Unit: Not yet known

	1
155.	Meng, Y. et al. (1997). "Inhalation Studies with Drugs of Abuse", NIDA Research Monogragh 173:201-224.
156.	Meng, Y., et al. (1999). "Pharmacological effects of methamphetamine and other stimulants via inhalation exposure," <i>Drug and Alcohol Dependence</i> . 53:111-120.
 157.	Office Action mailed 8/13/2003 for US application 10/153,313 filed 05/21/2002 "Delivery of Benzodiazepines Through an Inhalation Route".
158.	Pankow, J. F. et al. (1997). "Conversion of Nicotine in Tobacco Smoke to Its Volatile and Available Free-Base Form through the Action of Gaseous Ammonia," <i>Environ. Sci. Technol.</i> 31:2428-2433.
159.	Pankow, J. (March 2000). ACS Conference-San Francisco-3/26/00. Chemistry of Tobacco Smoke. pp. 1-8.
160.	Seeman, J. et al. (1999). "The Form of Nicotine in Tobacco. Thermal Transfer of Nicotine and Nicotine Acid Salts to Nicotine in the Gas Phase," J. Agric. Food Chem. 47(12):5133-5145.
161.	Sekine, H. and Nakahara, Y. (1987). "Abuse of Smoking Methamphetamine Mixed with Tobacco: 1. Inhalation Efficiency and Pyrolysis Products of Methamphetamine," <i>Journal of Forensic Science</i> 32(5):1271-1280.
162.	Vapotronics, Inc. (1998) located at http://www.vapotronics.com.au/banner.htm , 11 pages, (visited on June 5, 2000).
163.	Ward, M. E. MD, et al. (December 1997). "Morphine Pharmacokinetics after Pulmonary Administration from a Novel Aerosol Delivery System," Clinical Pharmocology & Therapeutics 62(6):596-609.
164.	Wood, R.W. et al. (1996). "Generation of Stable Test Atmospheres of Cocaine Base and Its Pyrolyzate, Methylecgonidine, and Demonstration of Their Biological Activity." <i>Pharmacology Biochemistry & Behavior</i> . 55(2):237-248.

EXAMINER:	DATE CONSIDERED: